AXQ Capital LP Makes New $1.43 Million Investment in Boston Scientific Corporation $BSX

AXQ Capital LP purchased a new stake in Boston Scientific Corporation (NYSE:BSX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 14,692 shares of the medical equipment provider’s stock, valued at approximately $1,434,000. Boston Scientific comprises 0.5% of AXQ Capital LP’s holdings, making the stock its 21st largest position.

Other hedge funds have also recently bought and sold shares of the company. Steph & Co. acquired a new position in shares of Boston Scientific in the third quarter valued at approximately $25,000. Financial Consulate Inc. acquired a new position in Boston Scientific in the 3rd quarter valued at $25,000. Murphy & Mullick Capital Management Corp grew its holdings in Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 170 shares in the last quarter. FWL Investment Management LLC bought a new position in Boston Scientific during the 2nd quarter worth $26,000. Finally, United Community Bank lifted its holdings in shares of Boston Scientific by 115.7% during the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 147 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. JPMorgan Chase & Co. decreased their target price on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Mizuho reduced their price target on Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Citigroup dropped their price objective on Boston Scientific from $130.00 to $102.00 and set a “buy” rating for the company in a report on Thursday, February 5th. BTIG Research reiterated a “buy” rating on shares of Boston Scientific in a research report on Wednesday, February 4th. Finally, Evercore dropped their price target on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $108.36.

Boston Scientific Price Performance

BSX stock opened at $74.37 on Tuesday. The stock has a market cap of $110.36 billion, a price-to-earnings ratio of 38.33, a P/E/G ratio of 1.03 and a beta of 0.67. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The company has a 50 day simple moving average of $88.87 and a 200 day simple moving average of $96.32. Boston Scientific Corporation has a 1 year low of $72.69 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter in the previous year, the firm posted $0.70 earnings per share. The company’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Activity

In related news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the sale, the executive vice president owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.